{"groups":[{"description":"3 evaluable participants were recruited to dose level 0.","id":"FG000","title":"Period 1- Dose Level 0 - 36mg/m^2"},{"description":"3 evaluable participants were recruited to dose level 1, one of which experienced a dose limiting toxicity.","id":"FG001","title":"Period 2 - Dose Level 1 - 45mg/m^2"},{"description":"4 participants were recruited to dose level 1; three of which were evaluable for the maximum tolerated dose, one of which was deemed unevaluable due experiencing an SAE after the loading dose (20 mg/m\\^2) of carfilzomib and was replaced.","id":"FG002","title":"Period 3 - Dose Level 1 - 45mg/m^2"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}